Cimzia (Crohn's Disease) - Forecast and Market Analysis to 2022
|出版日期||內容資訊||英文 45 Pages
|Cimzia(克隆氏症)- 預測與市場分析 Cimzia (Crohn's Disease) - Forecast and Market Analysis to 2022|
|出版日期: 2014年01月31日||內容資訊: 英文 45 Pages||
本報告提供UCB的PEG化 抗TNFα抗體、Cimzia(certolizumab pegol)的治療方法調查分析、疾病概要和治療指南、競爭情形、產品資訊、主要國家的銷售額預測等，為您概述為以下內容。
The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.
UCB's Cimzia (certolizumab pegol) is a PEGylated Fab' fragment of a humanized mAb with specificity for human TNF-α. The Fab' fragment of this biologic was engineered with a single free cysteine residue in the hinge region, which enables The site-specific attachment of polyethylene glycol without affecting the ability of the Fab' fragment to bind to and neutralize TNF-α. Due to the absence of the Fc region in its structure, Cimzia does not cause antibody-dependent, cell-mediated cytotoxicity. Also, in contrast to Remicade and Humira, Cimzia does not increase apoptosis, a well-known phenomenon with other anti-TNF-α agents, which may be responsible for their associated side effects.